XORTX Therapeutics Inc. (XRTX.V)

CAD 1.62

(-7.43%)

Market Cap (In CAD)

5.63 Million

Revenue (In CAD)

-

Net Income (In CAD)

-2.85 Million

Avg. Volume

10.41 Thousand

Currency
CAD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.54-9.35
PE
-
EPS
-
Beta Value
-0.207
ISIN
CA98420Q3061
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Allen Warren Davidoff Ph.D.
Employee Count
-
Website
https://www.xortx.com
Ipo Date
2021-11-05
Details
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.